Amidst ongoing discussions about geopolitical developments and economic resilience, the Asian markets have shown a mixed performance, with some indices advancing while others remain cautious. In this environment, growth companies with high insider ownership stand out as they often signal strong confidence from those who know the business best.
| Name | Insider Ownership | Earnings Growth |
| Zhejiang Taotao Vehicles (SZSE:301345) | 27.9% | 31.5% |
| Suzhou Dongshan Precision Manufacturing (SZSE:002384) | 33.5% | 73.1% |
| Seojin SystemLtd (KOSDAQ:A178320) | 18% | 110.6% |
| SEERS (KOSDAQ:A458870) | 33.2% | 41.5% |
| Meitu (SEHK:1357) | 22.8% | 31.3% |
| Meiko Electronics (TSE:6787) | 19.2% | 30.1% |
| Jiangxi Fushine Pharmaceutical (SZSE:300497) | 21.1% | 55.9% |
| Guangzhou Tinci Materials Technology (SZSE:002709) | 38.4% | 28.3% |
| Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) | 14.1% | 41% |
| ASE Technology Holding (TWSE:3711) | 25.8% | 37.5% |
Let's dive into some prime choices out of the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: PATEO CONNECT Technology (Shanghai) Corporation provides smart cockpit and vehicle connectivity support services in China and Hong Kong, with a market cap of HK$25.45 billion.
Operations: The company's revenue primarily comes from Smart Cockpit Solutions, generating CN¥3.41 billion, and Vehicle Connectivity Support Services, contributing CN¥86.73 million.
Insider Ownership: 22.5%
Earnings Growth Forecast: 101.6% p.a.
PATEO CONNECT Technology (Shanghai) demonstrates strong growth potential with high insider ownership and no substantial insider selling in the past three months. The company forecasts revenue growth of 31% per year, outpacing the Hong Kong market, and earnings are expected to grow significantly. Recent strategic alliances with Xunce Technology and Saimo Technology aim to develop a robust token economy model, enhancing PATEO's technological ecosystem. Despite a volatile share price, these initiatives may strengthen its competitive position in the medium term.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Guangdong Huate Gas Co., Ltd is involved in the production and supply of gas and gas equipment both within China and internationally, with a market cap of CN¥19.80 billion.
Operations: The company's revenue segments include the production and supply of gas and gas equipment, serving both domestic and international markets.
Insider Ownership: 20%
Earnings Growth Forecast: 35.3% p.a.
Guangdong Huate Gas shows promising growth potential with significant insider ownership and no recent substantial insider trading. While its profit margins have declined from last year, the company is forecasted to achieve revenue growth of 20.8% per year, surpassing the Chinese market average. Earnings are expected to grow significantly at 35.3% annually over the next three years, though return on equity remains modestly projected at 13.9%. The share price has been highly volatile recently.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Acrobiosystems Co., Ltd. specializes in developing and manufacturing recombinant proteins, antibodies, and other biological reagents for pharmaceutical companies, biotechnology firms, and research institutions, with a market cap of CN¥12.99 billion.
Operations: The company's revenue primarily comes from the Research and Experimental Development segment, which generated CN¥872.65 million.
Insider Ownership: 35.2%
Earnings Growth Forecast: 27.7% p.a.
Acrobiosystems Ltd. is trading slightly below its fair value and showcases strong growth prospects with earnings expected to grow at 27.7% annually, outpacing the Chinese market. Revenue is also set to increase by 20.3% per year, exceeding market averages. Despite a volatile share price recently and an unstable dividend history, the company has announced a CNY 50 million share buyback program aimed at capital reduction, reflecting confidence in its future performance.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com